Completed PHASE3 INTERVENTIONAL 1-arm NCT01184846

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: CSL Behring

Conditions Chronic Inflammatory Demyelinating Polyneuropathy

Interventions 10% liquid formulation of human immunoglobulin

Updated 7 times since 2017 Last updated: Jun 21, 2024 Started: Nov 30, 2010 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01184846, this PHASE3 trial focuses on Chronic Inflammatory Demyelinating Polyneuropathy and remains completed. Sponsored by CSL Behring, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Brussels, Belgium , Edegem, Belgium , Feldberger Seenlandschaft, Germany , Ghent, Belgium , Göttingen, Germany , Helsinki, Finland , Itzehoe, Germany , Krakow, Poland , Leuven, Belgium and 12 more locations